vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Life360, Inc. (LIF). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $146.0M, roughly 1.2× Life360, Inc.). Life360, Inc. runs the higher net margin — 88.8% vs -0.7%, a 89.5% gap on every dollar of revenue. On growth, Life360, Inc. posted the faster year-over-year revenue change (26.4% vs 0.7%). Life360, Inc. produced more free cash flow last quarter ($36.6M vs $21.3M). Over the past eight quarters, Life360, Inc.'s revenue compounded faster (36.6% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.
AVNS vs LIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $146.0M |
| Net Profit | $-1.3M | $129.7M |
| Gross Margin | 47.5% | 75.1% |
| Operating Margin | 1.4% | 6.1% |
| Net Margin | -0.7% | 88.8% |
| Revenue YoY | 0.7% | 26.4% |
| Net Profit YoY | 99.7% | 1425.9% |
| EPS (diluted) | $-0.02 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $146.0M | ||
| Q3 25 | $177.8M | $124.5M | ||
| Q2 25 | $175.0M | $115.4M | ||
| Q1 25 | $167.5M | $103.6M | ||
| Q4 24 | $179.6M | $115.5M | ||
| Q3 24 | $170.4M | $92.9M | ||
| Q2 24 | $171.7M | $84.9M | ||
| Q1 24 | $166.1M | $78.2M |
| Q4 25 | $-1.3M | $129.7M | ||
| Q3 25 | $-1.4M | $9.8M | ||
| Q2 25 | $-76.8M | $7.0M | ||
| Q1 25 | $6.6M | $4.4M | ||
| Q4 24 | $-397.3M | $8.5M | ||
| Q3 24 | $4.3M | $7.7M | ||
| Q2 24 | $1.8M | $-11.0M | ||
| Q1 24 | $-900.0K | $-9.8M |
| Q4 25 | 47.5% | 75.1% | ||
| Q3 25 | 48.4% | 78.0% | ||
| Q2 25 | 52.6% | 78.4% | ||
| Q1 25 | 53.6% | 80.6% | ||
| Q4 24 | 54.6% | 74.0% | ||
| Q3 24 | 54.5% | 75.4% | ||
| Q2 24 | 55.7% | 75.0% | ||
| Q1 24 | 57.1% | 76.7% |
| Q4 25 | 1.4% | 6.1% | ||
| Q3 25 | 0.1% | 4.6% | ||
| Q2 25 | -42.6% | 1.7% | ||
| Q1 25 | 6.1% | 2.1% | ||
| Q4 24 | -233.0% | 4.9% | ||
| Q3 24 | 7.0% | -5.3% | ||
| Q2 24 | 3.7% | -2.8% | ||
| Q1 24 | 2.4% | -8.2% |
| Q4 25 | -0.7% | 88.8% | ||
| Q3 25 | -0.8% | 7.9% | ||
| Q2 25 | -43.9% | 6.1% | ||
| Q1 25 | 3.9% | 4.2% | ||
| Q4 24 | -221.2% | 7.4% | ||
| Q3 24 | 2.5% | 8.3% | ||
| Q2 24 | 1.0% | -12.9% | ||
| Q1 24 | -0.5% | -12.5% |
| Q4 25 | $-0.02 | $1.53 | ||
| Q3 25 | $-0.03 | $0.11 | ||
| Q2 25 | $-1.66 | $0.08 | ||
| Q1 25 | $0.14 | $0.05 | ||
| Q4 24 | $-8.64 | $0.14 | ||
| Q3 24 | $0.09 | $0.09 | ||
| Q2 24 | $0.04 | $-0.15 | ||
| Q1 24 | $-0.02 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $494.3M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $548.2M |
| Total Assets | $1.1B | $959.7M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $494.3M | ||
| Q3 25 | $70.5M | $455.7M | ||
| Q2 25 | $90.3M | $432.7M | ||
| Q1 25 | $97.0M | $168.9M | ||
| Q4 24 | $107.7M | $159.2M | ||
| Q3 24 | $89.0M | $159.0M | ||
| Q2 24 | $92.2M | $160.8M | ||
| Q1 24 | $75.8M | $73.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | $5.2M |
| Q4 25 | $778.2M | $548.2M | ||
| Q3 25 | $778.0M | $391.4M | ||
| Q2 25 | $776.3M | $366.7M | ||
| Q1 25 | $839.4M | $376.3M | ||
| Q4 24 | $828.5M | $358.5M | ||
| Q3 24 | $1.2B | $339.7M | ||
| Q2 24 | $1.2B | $326.7M | ||
| Q1 24 | $1.2B | $239.8M |
| Q4 25 | $1.1B | $959.7M | ||
| Q3 25 | $1.1B | $787.5M | ||
| Q2 25 | $1.0B | $753.6M | ||
| Q1 25 | $1.1B | $455.4M | ||
| Q4 24 | $1.2B | $441.6M | ||
| Q3 24 | $1.7B | $427.4M | ||
| Q2 24 | $1.7B | $405.9M | ||
| Q1 24 | $1.7B | $318.8M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $36.8M |
| Free Cash FlowOCF − Capex | $21.3M | $36.6M |
| FCF MarginFCF / Revenue | 11.8% | 25.1% |
| Capex IntensityCapex / Revenue | 3.8% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 0.28× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $86.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $36.8M | ||
| Q3 25 | $14.0M | $26.4M | ||
| Q2 25 | $6.8M | $13.3M | ||
| Q1 25 | $25.7M | $12.1M | ||
| Q4 24 | $57.9M | $12.3M | ||
| Q3 24 | $23.0M | $6.3M | ||
| Q2 24 | $27.8M | $3.3M | ||
| Q1 24 | $-8.0M | $10.7M |
| Q4 25 | $21.3M | $36.6M | ||
| Q3 25 | $7.0M | $25.6M | ||
| Q2 25 | $-4.2M | $12.7M | ||
| Q1 25 | $19.0M | $11.9M | ||
| Q4 24 | $53.1M | $11.2M | ||
| Q3 24 | $20.0M | $6.3M | ||
| Q2 24 | $21.9M | $3.2M | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | 25.1% | ||
| Q3 25 | 3.9% | 20.6% | ||
| Q2 25 | -2.4% | 11.0% | ||
| Q1 25 | 11.3% | 11.5% | ||
| Q4 24 | 29.6% | 9.7% | ||
| Q3 24 | 11.7% | 6.8% | ||
| Q2 24 | 12.8% | 3.8% | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | 0.2% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | 6.3% | 0.6% | ||
| Q1 25 | 4.0% | 0.1% | ||
| Q4 24 | 2.7% | 1.0% | ||
| Q3 24 | 1.8% | 0.0% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 0.0% |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 1.90× | ||
| Q1 25 | 3.89× | 2.75× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | 5.35× | 0.83× | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
LIF
Segment breakdown not available.
